30 281

Cited 62 times in

Comparison of cilostazol and clopidogrel after successful coronary stenting.

Authors
Lee, SW; Park, SW; Hong, MK; Lee, CW; Kim, YH; Park, JH; Kang, SJ; Han, KH; Kim, JJ; Park, SJ
Citation
The American journal of cardiology, 95(7):859-862, 2005
Journal Title
The American journal of cardiology
ISSN
0002-91491879-1913
Abstract
This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.
MeSH terms
AgedAngioplasty, Balloon, Coronary/adverse effects*Aspirin/therapeutic useCoronary Restenosis/etiologyCoronary Restenosis/prevention & control*FemaleHumansMaleMiddle AgedMyocardial Infarction/etiologyMyocardial Infarction/prevention & controlPlatelet Aggregation Inhibitors/therapeutic use*Prospective StudiesStents/adverse effects*Tetrazoles/therapeutic use*Thrombosis/etiologyThrombosis/prevention & controlTiclopidine/analogs & derivatives*Ticlopidine/therapeutic use*Treatment Outcome
DOI
10.1016/j.amjcard.2004.12.012
PMID
15781016
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Cardiology
AJOU Authors
강, 수진
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse